Minnesota is currently home to 2106 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias
Recruiting
The researchers are trying to find out more about Gastric Antral Vascular Ectasia (GAVE). This is a condition that affects the blood vessels in the stomach, leading to their enlargement and possible bleeding. It can also cause symptoms such as abdominal pain and nausea. By participating in this study, you will help us learn how often these symptoms occur and how they relate to stomach functioning.
Gender:
All
Ages:
19 years and above
Trial Updated:
04/25/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Gastric Antral Vascular Ectasia, Cirrhosis
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
Recruiting
This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis". Only participants who have completed that study... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/25/2024
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Investigator Site US212, Minneapolis, Minnesota
Conditions: Hidradenitis Suppurativa (HS)
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
Recruiting
This is a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with HFrEF/HFmrEF.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Fairview Health Services St Johns, Saint Paul, Minnesota
Conditions: Heart Failure
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Recruiting
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypotheses are that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per P... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0072), Saint Louis Park, Minnesota
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
04/25/2024
Locations: Research Site, Rochester, Minnesota
Conditions: Metastatic Castration-Sensitive Prostate Cancer
A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C
Recruiting
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Allina Health Cancer Institute, Minneapolis, Minnesota
Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
Recruiting
The primary purpose of this study is to assess the safety and tolerability of ALXN1850 versus asfotase alfa in pediatric participants with HPP previously treated with asfotase alfa.
Gender:
All
Ages:
Between 2 years and 11 years
Trial Updated:
04/25/2024
Locations: Research Site, Minneapolis, Minnesota
Conditions: Hypophosphatasia
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States
Recruiting
Multi-center, prospective non-interventional study to collect data on the early use of ADSTILADRIN in the US. Data will be collected from participants, caregivers and prescribing physicians in a real-world setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Ferring Investigational Site, Rochester, Minnesota
Conditions: Bladder Cancer
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Recruiting
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/25/2024
Locations: M Health Fairview University of Minnesota Medical Center - East Bank, Minneapolis, Minnesota
Conditions: Pulmonary Arterial Hypertension
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Recruiting
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
04/25/2024
Locations: Retina Consultants of Minnesota, Minneapolis, Minnesota
Conditions: Geographic Atrophy of the Macula, Macular Degeneration
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
Recruiting
This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus in patients who have previously received 177Lu-DOTATATE for midgut neuroendocrine tumor (NET) that has spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable). PRRT is a type of radiation therapy for which a radioactive chemical is linked to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Metastatic Midgut Neuroendocrine Tumor, Unresectable Midgut Neuroendocrine Tumor, Metastatic Midgut Neuroendocrine Tumor G1, Metastatic Midgut Neuroendocrine Tumor G2